New identity reflects Company's evolution into an innovative data driven biotech company leveraging MITOLINE and mitochondrial carrier biology across oncology and inflammatory metabolic diseases Neve ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

The La Jolla-based research institute continues its founding principle of collaboration across multiple fields ...

Researchers at the Weill Institute for Cell and Molecular Biology have uncovered new evidence that two major types of gene-controlling DNA sequences, promoters and enhancers, operate with a shared ...

The FDA cleared a second arm for enrollment in the trial after one NSCLC patient demonstrated a complete response to the non-boosted therapy.

As of Friday, February 27, ImmunityBio, Inc.’s IBRX share price has dipped by 7.02%, which has investors questioning if this is right time to buy.

Advancing Research, Awareness, and Targeted Youth Advocacy for Women Diagnosed with Breast Cancer Before Age 40 DENVER, ...

The trials in breast, lung, and colorectal cancer, supported by ARPA-H, will focus on guiding decisions across different lines of therapy using serial biopsies and tumor profiling.

The field of cancer genetics and oncogenomics is undergoing a transformative shift as multi-omics approaches become central to understanding the complex ...

A phase 2 trial showed that combining targeted radiotherapy with PD-1 blockade and a bevacizumab biosimilar can elicit responses in advanced liver cancer.

Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December ...

Tidewave Bio, a biotechnology company developing a universal, biopsy-native immunotherapy platform for solid tumors, today announced the appointment of Prof. Alexander M.M. Eggermont, MD, PhD, as Head ...